Euglena Co., Ltd.
Stock Price Chart
2026/08/23 UpdatedPrice Trend
2026/08/23 UpdatedPrice & Trading Details
2026/08/23 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2021/08/13 | ¥-3.20 | ¥-0.94 | +70.6% |
| 2021/05/13 | ¥-3.20 | ¥1.77 | +155.3% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.6M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
986.1K | 0.00% | |
|
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E
|
711.1K | 0.00% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
241.5K | +4.75% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
159.3K | +1.42% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
132.8K | +1.70% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥2 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥44,392M | ¥46,482M | ¥47,618M | ¥50,370M |
| Gross Profit | ¥30,996M | ¥31,774M | ¥33,267M | ¥35,033M |
| Operating Income | -¥3,456M | -¥1,465M | ¥301M | ¥3,123M |
| Pretax Income | -¥1,863M | -¥1,633M | ¥173M | ¥2,354M |
| Net Income | -¥2,672M | -¥2,652M | -¥650M | -¥805M |
| EPS | -¥23.83 | -¥22.76 | -¥4.77 | -¥5.90 |
| Operating Margin | -7.79% | -3.15% | 0.63% | 6.20% |
| Balance Sheet | ||||
| Total Assets | ¥57,275M | ¥59,619M | ¥73,256M | ¥72,332M |
| Total Equity | ¥19,351M | ¥20,213M | ¥31,704M | ¥30,958M |
| Total Liabilities | ¥37,924M | ¥39,406M | ¥41,552M | ¥41,374M |
| Cash | ¥9,954M | ¥15,791M | ¥20,631M | ¥21,163M |
| Interest-bearing Debt | ¥22,220M | ¥25,071M | ¥25,917M | ¥27,680M |
| Equity Ratio | 33.79% | 33.90% | 43.28% | 42.80% |
| D/E Ratio | 1.15 | 1.24 | 0.82 | 0.89 |
| Cash Flow | ||||
| Operating CF | ¥924M | ¥658M | ¥2,645M | ¥5,188M |
| Investing CF | ¥1,233M | -¥646M | -¥7,990M | -¥585M |
| Financing CF | -¥2,993M | ¥5,828M | -¥485M | -¥2,428M |
| Free CF | ¥428M | -¥35M | ¥1,913M | ¥4,593M |
| Efficiency | ||||
| ROE | -13.81% | -13.12% | -2.05% | -2.60% |
| ROA | -4.67% | -4.45% | -0.89% | -1.11% |
Latest IR Information
-
【Euglena】Q1 FY2026 Financial Results | Sales of ¥13,197 million (+10.6% YoY)
In the first quarter of the fiscal year ending December 2026, sales reached ¥13,197 million (up 10.6% YoY), operating profit was ¥837 million (up 35.4%), and net loss improved to ¥32 million. The healthcare segment performed steadily, and the consolidated...
Read more -
Q1 FY2026 Earnings Explanation Materials
G.energy Inc. reports its Q1 FY2026 financial results. Revenue increased by 11% YoY, operating profit surged significantly, and net profit narrowed to a loss. Progress in overseas expansion and new product launches is also noted.
Read more -
(Correction) Partial Correction to the Financial Summary for the Fiscal Year Ending December 2025 (Japanese GAAP) (Consolidated)
Announcement of a partial correction to the financial summary for the fiscal year ending December 2025. The amount of offset accumulated deficits was revised from 3,558 million yen to 3,580 million yen.
Read more -
Notice on the Determination of the Decrease Ratio of Net Assets
Dividend of 2 yen per share based on December 31, 2025, total dividend amount of 273,156,876 yen, dividend source is other capital surplus, effective date is March 25, 2026.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥400
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae in Japan. It operates through there segments: Healthcare Business; Biofuel Business; and Other businesses. The company manufactures and sells health foods and cosmetics utilizing microalgae, such as euglena and chlorella. In addition, the company develops biofuel technology and environmental related technology for microalgae and industrial waste oil; development and research in agriculture business comprising feed and fertilizer, bioinformatics, and social businesses; and invests in biotechnology related businesses. Further, the company provides genome analysis services. Euglena Co., Ltd. was incorporated in 2005 and is headquartered in Tokyo, Japan.
